Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Research is a top priority at Dana-Farber/Boston Children's Childhood Brain Tumor Center. Our physicians work continuously to translate laboratory findings into clinical therapies and find ways to improve survival while reducing the toxicity and long-term
impact of treatment.
Our researchers investigate pediatric brain tumor topics such as anti-tumor medications, genetic markers on tumor cells, and the long-term effects of treatment and ways to minimize these effects.
At Dana-Farber/Boston Children's, we have an unparalleled depth of experience in developing new treatments for brain tumors through clinical trials.
Our research and clinical trials have made us a leader in improving survival rates for hard-to-treat pediatric brain tumors like medulloblastoma and atypical teratoid rhabdoid tumor (ATRT). We also were the first pediatric hospital to install a mobile “intraoperative MRI,” which allows surgeons to obtain images while the patient is still under
anesthesia and to perform further procedures as needed.
In addition to launching our own clinical trials, we also offer trials available through collaborative groups such as the Children's Oncology Group (COG) and
the Pacific Pediatric Neuro-oncology Consortium (PNOC). We are also the New England Phase I Center of the Children's Oncology Group. If your child has a progressive
or recurrent tumor, she may be eligible for a number of clinical trials available through these groups, or from one of our independent clinical investigators.
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
This is a two arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC) that looks to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma
or atypical teratoid rhabdoid tumor (ATRT).
Principal Investigator: Susan N. Chi, MD
New Patient Appointments
Find answers to common questions about clinical trials for
childhood cancer, including whether or not a clinical trial may be the right
choice for your child. You can also email your questions to email@example.com